Synthesis of Plasmin‐Loaded Fe3O4@CaCO3 Nanoparticles: Towards Next‐Generation Thrombolytic Drugs
Source abstract
Abstract
Abstract A major obstacle in the development of the next‐generation of thrombolytic drugs has been the fact that plasmin – a serine protease that dissolves fibrin in blood clots – despite being the only enzyme suitable for the clot cleavage, is still not used in practice due to its rapid inactivation. Here we point to a potential solution to this problem by developing a magnetically controlled system for targeted delivery and recrystallization‐driven release of plasmin showing therapeutic potential.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Protease and Inhibitor Mechanisms · Enzyme Production and Characterization
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
International Institute “Solution Chemistry of Advanced Materials and Technologies” (SCAMT) ITMO University 9, Lomonosova str. Saint Petersburg 191002 Russian Federation
Institute of Experimental Medicine 12, Akademika Pavlova str. Saint Petersburg 197376 Russian Federation
Centre of Preclinical Translational Research Almazov National Medical Research Centre 2, Akkuratova str. Saint Petersburg 197341 Russian Federation
Funding
Russian Science Foundation
References (58)
Show source-provided references
1. 10.1055/s-2007-100503810.1055/s-2007-1005038 ↗
2. 10.1111/j.1432-1033.1976.tb10875.x10.1111/j.1432-1033.1976.tb10875.x ↗
3. 10.1172/JCI10388510.1172/JCI103885 ↗
4.
5. 10.1055/s-0037-161612710.1055/s-0037-1616127 ↗
6. 10.1016/j.thromres.2008.06.01910.1016/j.thromres.2008.06.019 ↗
7. 10.1007/s12975-014-0376-410.1007/s12975-014-0376-4 ↗
8. 10.1038/srep0158710.1038/srep01587 ↗
9.
10. 10.1016/0016-7037(87)90155-410.1016/0016-7037(87)90155-4 ↗
11. 10.1351/pac19976905092110.1351/pac199769050921 ↗
12. 10.1016/S0022-0248(01)02082-610.1016/S0022-0248(01)02082-6 ↗
13.
14. 10.1002/ange.20110431610.1002/ange.201104316 ↗
15. 10.1002/anie.20110431610.1002/anie.201104316 ↗
16. 10.1128/AEM.01349-1410.1128/AEM.01349-14 ↗
17. 10.3390/ma911094410.3390/ma9110944 ↗
18. 10.1016/j.apt.2016.02.01410.1016/j.apt.2016.02.014 ↗
19.
20. 10.1517/17425247.2015.104953010.1517/17425247.2015.1049530 ↗
21. 10.1021/cg100631v10.1021/cg100631v ↗
22.
23. 10.1021/la036177z10.1021/la036177z ↗
24. Brecevic L. · J. Chem. Soc. · 1996 · 92 · 1017
25. 10.2138/am.2012.398310.2138/am.2012.3983 ↗
26. 10.3390/ijms1705063910.3390/ijms17050639 ↗
27. 10.1007/s00396-013-2960-710.1007/s00396-013-2960-7 ↗
28. 10.1186/s12951-015-0111-710.1186/s12951-015-0111-7 ↗
29.
30. 10.3390/pharmaceutics1004016710.3390/pharmaceutics10040167 ↗
31. Costa L. · Adv Tissue Eng Regen Med Open Access · 2017 · 3 · 336
32.
33. 10.3390/nano902017910.3390/nano9020179 ↗
34. 10.3389/fbioe.2015.0019510.3389/fbioe.2015.00195 ↗
35.
36. 10.1016/j.msec.2012.08.02610.1016/j.msec.2012.08.026 ↗
37. Zhou H. · Int. J. Nanomed. · 2015 · 10 · 4255
38. 10.1016/S0022-0248(01)02164-910.1016/S0022-0248(01)02164-9 ↗
39. 10.1021/cg300521310.1021/cg3005213 ↗
40.
41. 10.1208/s12249-011-9593-210.1208/s12249-011-9593-2 ↗
42. 10.1021/acsomega.7b0185910.1021/acsomega.7b01859 ↗
43. 10.1039/c1mb05147d10.1039/c1mb05147d ↗
44.
45. Lee J.-A. · Int. J. Nanomed. · 2015 · 10 · 2273
46. 10.3389/fphar.2018.0055910.3389/fphar.2018.00559 ↗
47. 10.2147/IJN.S7881410.2147/IJN.S78814 ↗
48. 10.1021/ja803958510.1021/ja8039585 ↗
49. 10.1039/B402617A10.1039/B402617A ↗
50. 10.1016/j.msec.2014.04.05010.1016/j.msec.2014.04.050 ↗
51. 10.1016/0378-4274(92)90208-210.1016/0378-4274(92)90208-2 ↗
52.
53. 10.1006/jsbi.1998.402710.1006/jsbi.1998.4027 ↗
54. 10.1016/j.jasms.2004.05.00410.1016/j.jasms.2004.05.004 ↗
55. 10.1042/bj265032710.1042/bj2650327 ↗
56. 10.1111/ijlh.1268810.1111/ijlh.12688 ↗
57. 10.1016/j.mattod.2015.08.02210.1016/j.mattod.2015.08.022 ↗
58. 10.1039/C5TB02228B10.1039/C5TB02228B ↗